Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases... Show more
The RSI Indicator for IPSEY moved out of oversold territory on August 07, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In of the 26 cases the stock moved higher. This puts the odds of a move higher at .
IPSEY moved above its 50-day moving average on August 07, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IPSEY advanced for three days, in of 149 cases, the price rose further within the following month. The odds of a continued upward trend are .
IPSEY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 223 cases where IPSEY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on August 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IPSEY as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IPSEY turned negative on August 05, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPSEY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.113) is normal, around the industry mean (16.657). P/E Ratio (20.110) is within average values for comparable stocks, (72.172). Projected Growth (PEG Ratio) (0.741) is also within normal values, averaging (4.696). IPSEY has a moderately low Dividend Yield (0.013) as compared to the industry average of (0.031). P/S Ratio (2.396) is also within normal values, averaging (40.190).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IPSEY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry PharmaceuticalsGeneric
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
PIE | 22.75 | 0.12 | +0.53% |
Invesco DW Emerging Markets Momt ETF | |||
VGSR | 10.40 | 0.03 | +0.33% |
Vert Global Sustainable Real Estate ETF | |||
SEPT | 33.36 | 0.06 | +0.18% |
AllianzIM U.S. Large Cp Buffer10 Sep ETF | |||
TDTT | 24.27 | -0.02 | -0.08% |
FlexShares iBoxx 3Yr Target Dur TIPS ETF | |||
NNOV | 28.06 | -0.04 | -0.12% |
Innovator Growth-100 Pwr Buffr ETF - Nov |
A.I.dvisor tells us that IPSEY and LBTSF have been poorly correlated (+15% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IPSEY and LBTSF's prices will move in lockstep.
Ticker / NAME | Correlation To IPSEY | 1D Price Change % | ||
---|---|---|---|---|
IPSEY | 100% | N/A | ||
LBTSF - IPSEY | 15% Poorly correlated | N/A | ||
LVRLF - IPSEY | 9% Poorly correlated | +19.28% | ||
HYPMY - IPSEY | 7% Poorly correlated | +4.58% | ||
IPSEF - IPSEY | 6% Poorly correlated | N/A | ||
INDV - IPSEY | 5% Poorly correlated | +1.25% | ||
More |
Ticker / NAME | Correlation To IPSEY | 1D Price Change % |
---|---|---|
IPSEY | 100% | N/A |
Pharmaceuticals: Generic industry (227 stocks) | 12% Poorly correlated | -1.78% |